Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- MBX
- Price
- 42.39
- Stock movement up
- +1.30 (3.16%)
- Company name
- MBX Biosciences, Inc. Common Stock
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.90B
- Ent value
- 1.69B
- Price/Sales
- 8573.91
- Price/Book
- 4.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 314.37%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MBX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 8573.91 |
| Price to Book | 4.91 |
| EV to Sales | 7625.32 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.90M |
| EPS (TTM) | -2.35 |
| FCF per share (TTM) | -2.31 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 222.00K |
| Gross profit (TTM) | -66.00K |
| Operating income (TTM) | -90.87M |
| Net income (TTM) | -80.50M |
| EPS (TTM) | -2.35 |
| EPS (1y forward) | -3.19 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -29.73% |
| Operating margin (TTM) | -40932.43% |
| Profit margin (TTM) | -36259.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 223.13M |
| Net receivables | 0.00 |
| Total current assets | 397.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.13M |
| Total assets | 400.08M |
| Accounts payable | 3.77M |
| Short/Current long term debt | 623.00K |
| Total current liabilities | 12.06M |
| Total liabilities | 12.54M |
| Shareholder's equity | 387.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -77.69M |
| Capital expenditures (TTM) | 1.23M |
| Free cash flow (TTM) | -78.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -20.77% |
| Return on Assets | -20.12% |
| Return on Invested Capital | -20.76% |
| Cash Return on Invested Capital | -20.35% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 41.48 |
| Daily high | 43.98 |
| Daily low | 40.10 |
| Daily Volume | 778K |
| All-time high | 43.14 |
| 1y analyst estimate | 59.25 |
| Beta | - |
| EPS (TTM) | -2.35 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 23 Mar 2026 |
Downside potential
Loading...
Downside potential data
| MBX | S&P500 | |
| Current price drop from All-time high | -1.74% | -0.89% |
| Highest price drop | -77.71% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -39.78% | -2.49% |
| Avg time to new high | 32 days | 6 days |
| Max time to new high | 278 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.90B
Marketcap category
Small-cap
Description
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Employees
43
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page